LinksHomepageStock List Search by Ticker News Login |
Bristol-myers Squibb Company (NYSE:BMY)
|
|
The following stock analysis is based on 10.4 years of data (i.e. since Oct 31, 2012). All the stock history has been downloaded.
Bristol-myers Squibb Company trades on the NYSE exchange in USD dollars.
It is in the sector.
It is currently trading at $69.31 ($68.2 the previous day).It pays a 3.21% dividend.
The next reporting date is in 26 days (2023 04 27).
CNN estimates profits for the upcoming quarter will be $1.99 per share ($11.6B). The current Canada / US exchange rate is 1.3511.
Over the past 12 months, $0 worth of shares have been purchased and $47423668 worth of shares have been sold by insiders.
The year over year average increase is 1.5% per year assuming steady exponential growth. The actual 5 year average is 4.84. Details on the individual increase in one year intervals is provided below.
| Past Performance | Average Price | Percent Change | |
|---|---|---|---|
| 1 year | 73.592078873239 | 13.7 | + Above Average |
| 2 year | 64.70091147541 | 5.5 | + Above Average |
| 3 year | 61.325884722222 | 20.8 | + Above Average |
| 4 year | 50.786098630137 | -5.7 | - Below Average |
| 5 year | 53.827642585551 | -10.1 | - Below Average |
The worst drop it has had in recent years is -44.3%. It has a shape to the stock curve, which means
| DAYS AG0 | PRICE | |
| 10 | 66.53 | RISING |
| 30 | 71.4 | DROPPING |
| 60 | 74.15 | DROPPING |
| 150 | 72.21 | RISING |
| 365 | 71.02 | RISING |
| 800 | 66.54 | RISING |
| 1200 | 61.28 | RISING |
| 1600 | 53.39 | RISING |
| 2000 | 63.8 | DROPPING |
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior TherapyFri, 31 Mar 2023 12:07:00 PRINCETON, N.J., March 31, 2023--BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy... Read Full Article |
Bristol Myers' Flagship Opdivo Shows Long Term Durable Benefits In Lung Cancer PatientsThu, 30 Mar 2023 18:18:04 Bristol Myers Squibb and Co (NYSE: BMY) announced three-year follow-up results from the Phase 3 CheckMate -816 trial of Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small-cell-lung-cancer. The data demonstrated sustained clinical benefits with three ...... Read Full Article |
Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 77%Thu, 30 Mar 2023 14:00:33 Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...... Read Full Article |
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 TrialThu, 30 Mar 2023 13:10:00 PRINCETON, N.J., March 30, 2023--Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung...... Read Full Article |
How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesThu, 30 Mar 2023 13:00:01 Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.... Read Full Article |
How to Boost Your Portfolio with Top Medical Stocks Set to Beat EarningsWed, 29 Mar 2023 13:00:01 Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.... Read Full Article |
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should KnowTue, 28 Mar 2023 21:50:09 In the latest trading session, Bristol Myers Squibb (BMY) closed at $68.20, marking a +0.19% move from the previous day.... Read Full Article |
Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EUTue, 28 Mar 2023 19:22:07 Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.... Read Full Article |
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?Tue, 28 Mar 2023 14:15:00 These titans of big pharma just enrolled patients into phase 3 clinical trials for this promising blood thinner.... Read Full Article |
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?Tue, 28 Mar 2023 14:15:00 While growth stocks boomed in the era of easy money, value stocks have returned to form as the market's top performers in the current high interest rate environment. Now, value comes in many forms, such as a highly dependable dividend, ...... Read Full Article |
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque PsoriasisTue, 28 Mar 2023 10:59:00 PRINCETON, N.J., March 28, 2023--BMS Receives European Commission Approval of Sotyktu (deucravacitinib) Once-Daily Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis... Read Full Article |
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma DrugMon, 27 Mar 2023 15:35:03 Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.... Read Full Article |
Bristol Myers Squibb (BMY) Stock Moves -0.4%: What You Should KnowWed, 22 Mar 2023 21:50:09 Bristol Myers Squibb (BMY) closed at $67.24 in the latest trading session, marking a -0.4% move from the prior day.... Read Full Article |
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst SaysMon, 20 Mar 2023 16:21:15 Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced results from a Phase 2b clinical trial of TAK-279 (NDI-034858) in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients ...... Read Full Article |
Bristol-Myers Squibb (NYSE:BMY) Seems To Use Debt Quite SensiblyMon, 20 Mar 2023 12:00:20 The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...... Read Full Article |
2 Top Healthcare Stocks to Buy for the Long HaulFri, 17 Mar 2023 14:15:00 Let's consider two of them: Bristol Myers Squibb (NYSE: BMY) and Novo Nordisk (NYSE: NVO). Bristol Myers is one of the largest pharmaceutical companies in the world with a portfolio of products that focuses predominantly on oncology and immunology, the ...... Read Full Article |
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should KnowThu, 16 Mar 2023 21:50:09 In the latest trading session, Bristol Myers Squibb (BMY) closed at $67.10, marking a -0.56% move from the previous day.... Read Full Article |
Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week LowsThu, 16 Mar 2023 13:15:00 A positive consequence of a bear market is that there are plenty of good opportunities for investors to buy stocks at reduced prices. Two stocks that stand out in particular to me right now include Bristol Myers Squibb (NYSE: BMY) ...... Read Full Article |
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion and Diversity Goals and Health Equity CommitmentsWed, 15 Mar 2023 10:59:00 PRINCETON, N.J., March 15, 2023--Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion and Diversity Goals and Health Equity Commitments... Read Full Article |
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price NegotiationMon, 13 Mar 2023 19:18:58 Bristol Myers Squibb and Co's (NYSE: BMY) Eliquis, Pfizer Inc's (NYSE: PFE) Ibrance, and AbbVie Inc's (NYSE: ABBV) Imbruvica are expected to be among the ten top-selling drugs subject to U.S. price negotiations for 2026. The U.S. government can ...... Read Full Article |